I store placebokontrollerede kliniske undersøgelser var den procentdel af patienter, som oplevede en bivirkning, der mindede om hypersensitivitet, herunder urticaria, udslæt og allergiske reaktioner, lidt højere i Raptiva- gruppen (8%) end i placebogruppen (7%).
In large placebo-controlled clinical studies, the percentage of patients experiencing an adverse event suggestive of hypersensitivity, including urticaria, rash and allergic reactions was slightly higher in the Raptiva group (8%) than in the placebo group (7%).